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ABSTRACT
Cancer cells are characterized by aberrant growth aris-
ing from deregulated signalling pathways. The mam-
malian target of rapamycin (mTOR) pathway integrates
multiple growth signals coming from both intracellu-
lar and extracellular cues. In this short review, we sum-
marize what is known about the efficacy of targeting
the mTOR pathway to treat cancer patients, and we
explain the rationale behind promising new inhibitors
that could show more potent tumour growth inhibition
than did the first generation of these drugs.
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1. INTRODUCTION
Signal transduction pathways govern appropriately regu-
lated cell growth, division, and survival in human tis-
sues, but these pathways are often deregulated in
aggressive cancers that show seemingly uncontrolled
growth. This observation has led to the notion that if
the molecular cause of a cancer can be determined,
then the aberration on which a particular cancer de-
pends could be directly targeted 1.
The mammalian target of rapamycin (mTOR) sig-
nalling pathway has proved to be an excellent model
system for exploring this notion of personalized medi-
cine, because numerous mutations resulting in
hyperactivation of the pathway have been identified,
the hyperactivation is itself demonstrated by multiple
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downstream biomarkers, and a specific potent mTOR
inhibitor, rapamycin, has a long been safely used to
treat humans 2. In this review, we discuss the mutations
and molecular diagnosis of tumours with hyperactivated
mTOR signalling, clinical trials of rapamycin analogues,
the rationale behind second-generation non-rapamycin-
analogue mTOR inhibitors, and the ongoing early-phase
clinical trials using these agents.
2. ABERRANT ACTIVATION OF MTOR
The evolutionarily conserved (yeast to man) mTOR
protein kinase integrates multiple intracellular and ex-
tracellular signals representing growth conditions (en-
ergy, growth factor, and amino-acid availability, for
instance) to control downstream processes, including
translation of messenger RNA, cell growth, and prolif-
eration (Figure 1). Numerous mutations of upstream
regulators of mTOR signalling can lead to hyperac-
tivation, thus uncoupling mTOR activity from the cues
that normally modulate its activity, resulting in uncon-
strained cell growth 3. For example, the phosphoinositide
3 kinase (PI3K) signalling pathway is normally acti-
vated when growth factors bind transmembrane
receptors; it is inactivated by PTEN (the protein en-
coded by the phosphatase and tensin homolog gene)
when growth factors are not abundant. Similarly, ser-
ine/threonine kinase 11 [Stk11 (Lkb1)] negatively regu-
lates mTOR activity when cellular energy (adenosine
triphosphate) is in low supply, and the tuberous sclero-
sis complex (Tsc1/Tsc2) negatively regulates both of
those signals to mTOR. Consequently, cells lacking func-
tional PTEN, Stk11 (Lkb1), or Tsc2 exhibit deregulated,
constitutive signalling to mTOR, resulting in multiple
types of cancer 1–4.
3. RAPAMYCIN ANALOGUES: CLINICAL
TRIALS
Rapamycin, a natural product from soil bacteria, in-
hibits mTOR by simultaneously binding to a protein
called Fkbp12 and to the Fkbp12 rapamycin-binding
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(FRB) domain of mTOR. Because of its ability to inhibit
mTOR-dependent growth and proliferation of B and T
cells, rapamycin has long been used as an immuno-
suppressant (sirolimus) to prevent organ rejection, and
because of its ability to inhibit the fungal orthologue of
mTOR, it can also be used as an antifungal agent.
In clinical trials, rapamycin and three rapamycin ana-
logues—CCI-779 [temsirolimus (Torisel: Wyeth-Ayerst,
Charlotte, NC, U.S.A.)], RAD001 [everolimus (Certican:
Novartis Pharmaceuticals, St. Louis, MO, U.S.A.)], and
AP23573 (deforolimus: Ariad Pharmaceuticals, Cam-
bridge, MA, U.S.A., and Merck and Co., Whitehouse
Station, NJ, U.S.A.)—have been assessed for their effi-
cacy as anticancer agents 5,6. These compounds have
been tested alone and in combination with standard-of-
care agents for a wide variety of human cancers.
Based on preclinical testing, mTOR inhibitors were
predicted to be effective in the treatment of tumours
with genetic mutations that lead to overactivation of
mTOR signalling—for example, loss of PTEN, Stk11
(Lkb1), or Tsc2. Cells and tumours containing muta-
tions or deletions of these tumour suppressors exhibit
uncontrolled mTOR signalling and an increase in phos-
phorylation of the downstream targets Eif4Ebp1
(eukaryotic translation initiation factor 4E binding pro-
tein 1) and S6 kinase 7–9. Data from clinical trials
seem to support this hypothesis, because endometrial
tumours, which exhibit a high frequency of PTEN in-
activation, have responded favourably to treatment
with temsirolimus 10,11. Renal cell carcinoma also
exhibits some sensitivity to mTOR inhibitors, likely
because of the importance of mTOR signalling in the
expression of Hif1A (hypoxia inducible factor 1, al-
pha subunit), a key player in angiogenesis and the
growth of renal tumours 11,12. In fact, results from a
recent phase III clinical trial involving patients with
metastatic renal cell carcinoma indicate that
everolimus may be an effective option for patients
suffering from renal cancer 12. Furthermore,
temsirolimus was approved for the treatment of pa-
tients with renal carcinoma in May 2007 5. This evi-
dence indicates that overactive mTOR signalling (as a
result of genetic mutation, inactivation, or loss of key
tumour suppressors) may be used to identify patients
who would benefit from treatment with rapamycin
analogues. However, although rapamycin analogues
have been effective in the treatment of some tumours
that lack PTEN (such as those of the endometrium),
other cancers have been refractory to the effects of
mTOR inhibitors despite PTEN loss or mutation 13,14.
In these and other cases, results from clinical trials
have been disappointing to some who had high hopes
for this rationale-based chemotherapy 15.
4. SECOND-GENERATION MTOR
INHIBITORS
All of the above-described mTOR inhibitors undergo-
ing clinical trials are rapamycin analogues, and they
therefore inhibit only a portion of mTOR signalling—
FIGURE 1    The phosphoinositide 3 kinase (PI3K)–Akt–mammalian target of rapamycin (mTOR) pathway integrates multiple signals emanating
from inside and outside the cell. The rapamycin-sensitive mTOR complex 1 (mTORC1) responds to energy balance, growth factors, and availability
of metabolites. The rapamycin-insensitive mTOR complex 2 (mTORC2) promotes cell survival, but its regulation is less well characterized. ATP =
adenosine triphosphate; Lkb1 = serine/threonine kinase 11 (Stk11); Tsc2 = tuberous sclerosis 2 protein; PTEN = protein encoded by the
phosphatase and tensin homolog gene; mRNA = messenger RNA.FURIC et al.
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the portion effected by the rapamycin-sensitive mTOR
complex 1 (mTORC1) 16. It has been hypothesized that
inhibition of both mTORC1 and the rapamycin-insensi-
tive mTOR complex 2 (mTORC2) would be a more ef-
fective means of treating such tumours 17,18, because
inhibition of mTORC1 with rapamycin actually leads to
an upregulation of mTORC2-dependent survival signal-
ling through the PI3K-Akt pathway by suppressing a
negative feedback loop 19. Consistent with this reason-
ing, it has been shown that dual inhibition of mTOR and
PI3K–Akt is an effective means to target PTEN-defi-
cient tumours 20. Developing mTOR inhibitors that tar-
get the kinase domain has been proposed as an effective
means to block the activities of both mTORC1 and
mTORC2 17,18, and a new wave of clinical trials has
commenced using a second generation of mTORC1 and
2 inhibitors. The agent OSI-027 (OSI Pharmaceuticals,
Melville, NY, U.S.A.), for example, is an mTORC1
and 2 inhibitor currently being evaluated (phase I) to
determine the maximum tolerated dose in patients with
lymphoma or solid tumours. Similarly, BEZ235
(Novartis Pharmaceuticals) is being evaluated (phase
I and II) to determine dosing and effectiveness in treat-
ing advanced solid tumours, particularly those in pa-
tients with Cowden syndrome (caused by PTEN loss).
A third mTORC1 and 2 inhibitor, XL765 (Exelixis, San
Francisco, CA, U.S.A.) is being tested (phase I) alone
and in combination therapies.
5. SUMMARY
As a whole, exploiting the mTOR signalling pathway
and its aberrant activation has provided strong proof
that the age of personalized medicine based on
molecular diagnoses is well underway. Progress to
this point indicates that further elucidation of the
mechanisms involved in predicting sensitivity to
rapamycin and analogues is possible, as is develop-
ment of new, more potent mTOR inhibitors for the
treatment of cancer. It is important to keep in mind
that the signalling pathways inhibited by rapamycin
analogues and by mTORC1 and 2 inhibitors are likely
crucial for the growth, proliferation, and survival of
possibly all human cells, and therefore such compounds
should be effective treatments against most tumours
in the same way that traditional chemotherapies are.
However, the notion of “oncogene addiction” suggests
that, if a particular aberration is driving tumour sur-
vival, then it may be possible to selectively target the
cancer while merely inducing growth arrest or
cytostasis in healthy tissues.
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